Nuclear Receptor & In Vitro Toxicology Solutions™

Get all the latest news from INDIGO

  • This field is for validation purposes and should be left unchanged.

  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • ASSAYS
    • By Receptor
    • By Disease State
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Toxicology Solutions
      • In Vitro Toxicology Platform
      • Gene Expression
      • MDR1 / Human P-Glycoprotein
      • Discovery Toxicology
      • Environmental Monitoring
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
    • Ortholog Assays
    • Custom Assay Development
  • TECHNOLOGY
    • Nuclear Receptor Overview
    • Assay Kit Platform & Formats
    • Nuclear Receptor Profiling & Panels
    • Environmental Testing Solutions
    • Growth Factor Receptors
    • upcyte® Hepatocytes
    • FAQ
  • RESOURCES
    • Technical Manuals
    • Safety Data Sheets
    • Scientific Whitepapers from INDIGO
    • Scientific Posters
    • New Research Publications
    • Nuclear Receptor Resource
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Request Information
    • Distributors
    • Terms & Conditions
      • Product Policies
      • Limited Use Disclosures
  • BLOG

Nuclear Receptor & In Vitro Toxicology Solutions™

Search site...

± α β γ δ Δ ε ζ κ ω ö ® ™ µ

  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • ASSAYS
    • By Receptor
    • By Disease State
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Toxicology Solutions
      • In Vitro Toxicology Platform
      • Gene Expression
      • MDR1 / Human P-Glycoprotein
      • Discovery Toxicology
      • Environmental Monitoring
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
    • Ortholog Assays
    • Custom Assay Development
  • TECHNOLOGY
    • Nuclear Receptor Overview
    • Assay Kit Platform & Formats
    • Nuclear Receptor Profiling & Panels
    • Environmental Testing Solutions
    • Growth Factor Receptors
    • upcyte® Hepatocytes
    • FAQ
  • RESOURCES
    • Technical Manuals
    • Safety Data Sheets
    • Scientific Whitepapers from INDIGO
    • Scientific Posters
    • New Research Publications
    • Nuclear Receptor Resource
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Request Information
    • Distributors
    • Terms & Conditions
      • Product Policies
      • Limited Use Disclosures
  • BLOG

In vitro assessment of human nuclear hormone receptor activity and cytotoxicity of the flame retardant mixture FM 550 and its triarylphosphate and brominated components

Print Friendly, PDF & Email

ABSTRACT

Firemaster®550 (FM 550) is a mixture of brominated and triarylphosphate flame retardants used in polyurethane foam-based products. The primary components are also used in numerous other applications and are thus common household and industrial contaminants. Our previous animal studies suggested that FM 550 exposure may alter metabolism and cause weight gain. Employing human nuclear receptor (NR) luciferase reporter assays, the goal of this study was to evaluate the agonist actions of FM550 and its constituent compounds at NRs with known roles in establishing or regulating energy balance. FM 550 was found to have significant agonist activity only at the master regulator of adipocyte differentiation PPAR. As a result, the concentration response relationships and relative activities of FM 550 at PPAR were investigated in more detail with the contribution of each chemical component defined and compared to the activities of the prototypical PPAR environmental ligands triphenyltin and tributyltin. The resulting data indicated that the primary metabolic disruptive effects of FM 550 were likely mediated by the activity of the triarylphosphates at PPAR, and have identified TPP as a candidate metabolic disruptor that also acts as a cytotoxicant.

To read the full article click HERE.

Date of publication: 28 April 2014; Science Direct: Elsevier, Toxicology Letters

Author information: Scott M. Belcher (1); Clifford J. Cookman (1); Heather B. Patisaul (2); & Heather M. Stapleton (3)

(1) Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0575, USA
(2) Department of Biological Sciences, Center for Human Heath and the Environment, North Carolina State University, Raleigh, NC, USA
(3) Nicholas School of the Environment, Duke University, Durham, NC, USA

Filed Under: New Publications Tagged With: LXR, PPAR, PPARγ, TR, TRa, TRb

INDIGO Biosciences - The right partner for all your discovery and toxicology needs.
Search site...
Click to Insert Symbols in Search

α β γ δ Δ ε ζ κ ® ™ µ

Want More Information?

Simply fill out this form and we'll be in touch!

Resource Quick Links

  • Technical Manuals & Product Listing
  • Safety Data Sheets
  • Sample Study Report
  • Study Work Order Form

3006 Research Drive, Suite A1, State College, PA, USA 16801

+1 (814) 234-1919

  • Home
  • Products
  • Request a Quote
  • FAQ

© 2022 INDIGO Biosciences, Inc. All Rights Reserved